MXPA05005574A - Compuestos calciliticos. - Google Patents

Compuestos calciliticos.

Info

Publication number
MXPA05005574A
MXPA05005574A MXPA05005574A MXPA05005574A MXPA05005574A MX PA05005574 A MXPA05005574 A MX PA05005574A MX PA05005574 A MXPA05005574 A MX PA05005574A MX PA05005574 A MXPA05005574 A MX PA05005574A MX PA05005574 A MXPA05005574 A MX PA05005574A
Authority
MX
Mexico
Prior art keywords
calcilytic compounds
compounds
calcilytic
methods
novel calcilytic
Prior art date
Application number
MXPA05005574A
Other languages
English (en)
Inventor
Joshi M Ramanjulu
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of MXPA05005574A publication Critical patent/MXPA05005574A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C217/04—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C217/28—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines
    • C07C217/30—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines having the oxygen atom of at least one of the etherified hydroxy groups further bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C217/04—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C217/28—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines
    • C07C217/30—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines having the oxygen atom of at least one of the etherified hydroxy groups further bound to a carbon atom of a six-membered aromatic ring
    • C07C217/32—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines having the oxygen atom of at least one of the etherified hydroxy groups further bound to a carbon atom of a six-membered aromatic ring the six-membered aromatic ring or condensed ring system containing that ring being further substituted
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C217/04—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C217/28—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines
    • C07C217/30—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines having the oxygen atom of at least one of the etherified hydroxy groups further bound to a carbon atom of a six-membered aromatic ring
    • C07C217/32—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines having the oxygen atom of at least one of the etherified hydroxy groups further bound to a carbon atom of a six-membered aromatic ring the six-membered aromatic ring or condensed ring system containing that ring being further substituted
    • C07C217/34—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines having the oxygen atom of at least one of the etherified hydroxy groups further bound to a carbon atom of a six-membered aromatic ring the six-membered aromatic ring or condensed ring system containing that ring being further substituted by halogen atoms, by trihalomethyl, nitro or nitroso groups, or by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/34—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Nutrition Science (AREA)
  • Immunology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)

Abstract

Se proporcionan compuestos novedosos calciliticos y metodos de usos de los mismos.
MXPA05005574A 2002-11-26 2003-11-25 Compuestos calciliticos. MXPA05005574A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42910502P 2002-11-26 2002-11-26
PCT/US2003/037461 WO2004047751A2 (en) 2002-11-26 2003-11-25 Calcilytic compounds

Publications (1)

Publication Number Publication Date
MXPA05005574A true MXPA05005574A (es) 2005-07-27

Family

ID=32393505

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA05005574A MXPA05005574A (es) 2002-11-26 2003-11-25 Compuestos calciliticos.

Country Status (33)

Country Link
US (6) US7514473B2 (es)
EP (1) EP1569892B1 (es)
JP (1) JP4489597B2 (es)
KR (2) KR101142697B1 (es)
CN (1) CN1325466C (es)
AP (1) AP2113A (es)
AR (1) AR042132A1 (es)
AU (1) AU2003291157C1 (es)
BR (1) BR0316544A (es)
CA (1) CA2507226C (es)
CO (1) CO5570664A2 (es)
CY (1) CY1113083T1 (es)
DK (1) DK1569892T3 (es)
EA (1) EA009603B1 (es)
ES (1) ES2388277T3 (es)
HK (1) HK1082914A1 (es)
IL (1) IL168704A (es)
IS (1) IS2897B (es)
MA (1) MA27528A1 (es)
MX (1) MXPA05005574A (es)
MY (1) MY143244A (es)
NO (1) NO332304B1 (es)
NZ (1) NZ540275A (es)
OA (1) OA12962A (es)
PE (1) PE20040845A1 (es)
PL (1) PL211571B1 (es)
PT (1) PT1569892E (es)
SI (1) SI1569892T1 (es)
TW (1) TWI316511B (es)
UA (1) UA81642C2 (es)
UY (1) UY28089A1 (es)
WO (1) WO2004047751A2 (es)
ZA (1) ZA200504104B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY28089A1 (es) 2002-11-26 2004-06-30 Smithkline Beecham Corp Compuestos calciliticos
EP1713758A4 (en) * 2004-02-06 2008-02-13 Smithkline Beecham Corp CALCILYTIC COMPOUNDS
UY30801A1 (es) * 2006-12-18 2008-07-03 Smithkline Beecham Corp Compuestos calciliticos
JP5025795B2 (ja) * 2008-06-05 2012-09-12 旭化成ファーマ株式会社 スルホンアミド化合物及びその用途
BRPI0922503A2 (pt) * 2008-12-24 2018-11-06 Daiichi Sankyo Company, Limited composto, composição farmacêutica, métodos para melhorar o metabolismo ósseo, e para previnir ou tratar osteoporose
GB201217330D0 (en) 2012-09-28 2012-11-14 Univ Cardiff Therapeutic for treating inflammatory lung disorders
WO2015196205A1 (en) * 2014-06-20 2015-12-23 Glaxosmithkline Llc Method of using calcilytic compounds to treat diseases of abnormal glucose or insulin levels

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE298506C (es)
US643656A (en) * 1898-09-03 1900-02-20 Francis Keil Mold for lock-cylinders and key-hubs.
ES421076A1 (es) 1973-12-01 1976-04-01 Andreu Sa Dr Procedimiento para la obtencion de 1-ariloxi-3-aralquilami-no-2-propanoles.
ES442062A1 (es) 1975-10-24 1977-04-01 Andreu Sa Dr Procedimiento para la obtencion de 1-ariloxi-2-hidroxi-3- alquilaminopropanos.
DE2644833A1 (de) * 1976-10-05 1978-04-20 Boehringer Sohn Ingelheim Neue 1-aryloxy-2-hydroxy-3-alkylenaminopropane und verfahren zu ihrer herstellung
CH618335A5 (es) * 1977-05-31 1980-07-31 Arnegger Richard E
US4234595A (en) * 1977-07-13 1980-11-18 Mead Johnson & Company 3-Indolyl-tertiary butylaminopropanols
IL56369A (en) * 1978-01-20 1984-05-31 Erba Farmitalia Alpha-phenoxybenzyl propanolamine derivatives,their preparation and pharmaceutical compositions comprising them
IT1101724B (it) * 1978-12-05 1985-10-07 Erba Carlo Spa Derivati morfolinici e fenossiprofanolaminici e procedimento per la loro preparazione
GB2014968A (en) 1978-02-24 1979-09-05 Pearson J Article handling apparatus
US4495352A (en) * 1979-02-13 1985-01-22 Mead Johnson & Company Heterocyclic substituted aryloxy 3-indolyl-tertiary butylaminopropanols
ES480066A1 (es) 1979-04-28 1980-04-01 Especialid Latin Medicam Unive Procedimiento de obtencion de 1-4-cloro-&,&-dimetil-benceno-etanamino-2-oxi-3 ariloxi propanos.
DE3544172A1 (de) * 1985-12-13 1987-06-19 Lentia Gmbh Neue kristalline salze von aryloxy-propanolaminen, verfahren zu ihrer herstellung und ihre verwendung
FR2601008B1 (fr) * 1986-07-03 1990-03-30 Sanofi Sa Procede de synthese stereospecifique de derives de l'indole
DD298506A5 (de) * 1988-12-30 1992-02-27 Ernst-Moritz-Arndt-Universitaet Greifswald,De Verfahren zur herstellung halogensubstituierter 1-phenoxy-3-alkylamino-propan-2-ole
DE4040186A1 (de) 1989-12-20 1991-06-27 Hoechst Ag Hypoglykaemisch aktive propandiolaminderivate mit insulin-aehnlicher wirkung und deren verwendung, neue propandiolaminderivate, diese substanzen enthaltende pharmazeutische zubereitungen und ihre verwendung zur behandlung von krankheiten
HN1996000101A (es) 1996-02-28 1997-06-26 Inc Pfizer Terapia combinada para la osteoporosis
US6818660B2 (en) * 1996-04-09 2004-11-16 Nps Pharmaceuticals, Inc. Calcilytic compounds
WO1997037967A1 (en) 1996-04-09 1997-10-16 Nps Pharmaceuticals, Inc. Calcilytic compounds
US20020019440A1 (en) * 1996-11-05 2002-02-14 Virbac Sa Aryloxypropanolamine derivatives, method of preparation and applications thereof
US7202261B2 (en) * 1996-12-03 2007-04-10 Nps Pharmaceuticals, Inc. Calcilytic compounds
TW483881B (en) * 1996-12-03 2002-04-21 Nps Pharma Inc Calcilytic compounds
WO1998044925A1 (en) 1997-04-04 1998-10-15 Smithkline Beecham Corporation Calcilytic compounds
UY24949A1 (es) * 1997-04-08 2001-04-30 Smithkline Beecham Corp Compuestos calcilíticos
DE19913753A1 (de) 1998-04-01 1999-10-07 Mannesmann Rexroth Ag Verfahren zur Bildung des Mittelwertes
AR014975A1 (es) 1998-04-08 2001-04-11 Nps Pharma Inc Compuestos calciliticos, una composicion farmaceutica que los comprende, y el uso de los mismos para la fabricacion de un medicamento
AR018177A1 (es) * 1998-04-08 2001-10-31 Smithkline Beecham Corp Compuestos calciliticos, una composicion farmaceutica que los comprende y el uso de los mismos para la manufactura de un medicamento.
EP1104411A4 (en) * 1998-08-12 2002-10-24 Smithkline Beecham Corp CALCILYTIC COMPOUNDS
CA2340068A1 (en) * 1998-08-12 2000-02-24 Smithkline Beecham Corporation Calcilytic compounds
PE20001456A1 (es) * 1999-02-02 2001-01-28 Smithkline Beecham Corp Compuestos calcioliticos
AU6050000A (en) 1999-07-22 2001-02-13 Eli Lilly And Company Improved method of treating type ii diabetes and obesity
ECSP003590A (es) 1999-07-31 2002-02-25 Smithkline Beecham Corp Compuestos calcioliticos
US20030018203A1 (en) * 2002-07-17 2003-01-23 Largo Maria Amparo Calcilytic compounds
MY159417A (en) * 2000-01-24 2017-01-13 Smithkline Beecham Corp Calcilytic compounds
ES2296774T3 (es) 2000-07-21 2008-05-01 Smithkline Beecham Corporation Compuestos calcioliticos.
WO2002034204A2 (en) 2000-10-25 2002-05-02 Smithkline Beecham Corporation Calcilytic compounds
CN1520401A (zh) 2000-10-25 2004-08-11 ʷ��˿�������ȳ�ķ���޹�˾ 钙离子阻断化合物
WO2002072760A2 (en) * 2001-03-08 2002-09-19 Smithkline Beecham Corporation Pcra helicase inhibitors
US6864267B2 (en) * 2001-07-16 2005-03-08 Smithkline Beecham Corporation Calcilytic compounds
UY28089A1 (es) * 2002-11-26 2004-06-30 Smithkline Beecham Corp Compuestos calciliticos
US7491728B2 (en) * 2003-04-07 2009-02-17 Smithkline Beecham Corp. Pyrimidinone compounds as calcilytics
US20070010571A1 (en) * 2003-08-20 2007-01-11 Nitromed, Inc. Nitrosated and nitrosylated cardiovascular compounds, compositions and methods of use
WO2005030746A1 (en) 2003-09-24 2005-04-07 Glaxo Group Limited Calcilytic compounds
AR045799A1 (es) * 2003-09-24 2005-11-16 Glaxo Group Ltd Compuesto 6- oxo-2,5- dioxabiciclico y su uso para preparar una composicion farmaceutica
EP1713767A4 (en) 2004-02-06 2008-01-16 Smithkline Beecham Corp CALCILYTIC COMPOUNDS
NL1025457C1 (nl) 2004-02-11 2005-08-12 Rudolf Johannes Gerardus Hoorn Haspelrem.
EP1814535A4 (en) 2004-11-08 2008-06-04 Nitromed Inc NITROSED AND NITROSYLATED COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING EYE DISEASES
US20080306041A1 (en) 2005-01-21 2008-12-11 Garvey David S Cardiovascular Compounds Comprising Heterocyclic Nitric Oxide Donor Groups, Compositions and Methods of Use

Also Published As

Publication number Publication date
KR20110124806A (ko) 2011-11-17
AU2003291157C1 (en) 2011-05-12
WO2004047751A2 (en) 2004-06-10
US7514473B2 (en) 2009-04-07
EA009603B1 (ru) 2008-02-28
PE20040845A1 (es) 2004-11-28
JP4489597B2 (ja) 2010-06-23
US8399517B2 (en) 2013-03-19
IS2897B (is) 2014-09-15
PL211571B1 (pl) 2012-05-31
EP1569892A4 (en) 2010-09-15
CO5570664A2 (es) 2005-10-31
AU2003291157B2 (en) 2011-01-20
CN1741985A (zh) 2006-03-01
US9227914B2 (en) 2016-01-05
NO20053071L (no) 2005-06-22
AU2003291157A1 (en) 2004-06-18
KR20050086786A (ko) 2005-08-30
CN1325466C (zh) 2007-07-11
PT1569892E (pt) 2012-09-06
OA12962A (en) 2006-10-13
US20140057980A1 (en) 2014-02-27
US20130158114A1 (en) 2013-06-20
MY143244A (en) 2011-04-15
US8586631B2 (en) 2013-11-19
MA27528A1 (fr) 2005-09-01
HK1082914A1 (en) 2006-06-23
US7829594B2 (en) 2010-11-09
EP1569892B1 (en) 2012-06-13
JP2006507348A (ja) 2006-03-02
TWI316511B (en) 2009-11-01
SI1569892T1 (sl) 2012-09-28
US20110054021A1 (en) 2011-03-03
ES2388277T3 (es) 2012-10-11
EP1569892A2 (en) 2005-09-07
TW200510276A (en) 2005-03-16
CA2507226A1 (en) 2004-06-10
KR101142697B1 (ko) 2012-05-10
NO332304B1 (no) 2012-08-20
DK1569892T3 (da) 2012-08-27
US20060058391A1 (en) 2006-03-16
WO2004047751A3 (en) 2004-08-19
AP2113A (en) 2010-03-04
US8980950B2 (en) 2015-03-17
UY28089A1 (es) 2004-06-30
BR0316544A (pt) 2005-10-04
IS7880A (is) 2005-06-02
ZA200504104B (en) 2006-03-29
AP2005003320A0 (en) 2005-06-30
UA81642C2 (ru) 2008-01-25
EA200500878A1 (ru) 2005-10-27
AR042132A1 (es) 2005-06-08
PL376965A1 (pl) 2006-01-09
US20150183723A1 (en) 2015-07-02
US20090163589A1 (en) 2009-06-25
CY1113083T1 (el) 2016-04-13
IL168704A (en) 2010-12-30
CA2507226C (en) 2011-11-15
NZ540275A (en) 2007-11-30

Similar Documents

Publication Publication Date Title
SG145694A1 (en) Novel compounds
AU2003285934A1 (en) Analogs and prodrugs of buprenorphine
AU2003299585A8 (en) Water-soluble products and methods of making and using the same
ATE461217T1 (de) Glp-1-verbindungen
PL372926A1 (en) Piperidine-pyridazones and phthalazones as pde4 inhibitors
AU2003290592A1 (en) Antitumor benzoylsulfonamides
MY133625A (en) Peptide deformylase inhibitors
TW200613308A (en) Cyclobutanetetracarboxylate compound and preparation method thereof
TW200508233A (en) Chk-1 inhibitors
AP2002002547A0 (en) Calcilytic compounds.
TW200510276A (en) Calcilytic compounds
SG148154A1 (en) Benzannelated compounds as ppar activators
EP1383511A4 (en) CALCILYTIC COMPOUNDS
MXPA02011558A (es) Inhibidores de mmp-2/mp-9 novedosos.
MY133881A (en) "calcilytic compounds"
AU2003223634A1 (en) Peptide deformylase inhibitors
AU2003216848A1 (en) Deracemisation of amines
SG148860A1 (en) Stereospecific reduction of sapogen-3-ones
AU2003304490A1 (en) Peptide deformylase inhibitors
AU2002258437A1 (en) Peptide deformylase inhibitors
IL163899A0 (en) Peptide deformylase inhibitors
AU2002322035A1 (en) Peptide deformylase inhibitors
WO2004046103A3 (en) Arylpyridine compounds
AU2002255635A1 (en) Peptide deformylase inhibitors
AU2003212509A1 (en) Compounds for use as surfactants

Legal Events

Date Code Title Description
FG Grant or registration